Swedish Orphan Biovitrum AB (LTS:0MTD) EV-to-Revenue

: 4.79 (As of Today)

View and export this data going back to 2010. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Swedish Orphan Biovitrum AB's enterprise value is kr105,975 Mil. Swedish Orphan Biovitrum AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr22,122 Mil. Therefore, Swedish Orphan Biovitrum AB's EV-to-Revenue for today is 4.79.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-Revenue or its related term are showing as below:

LTS:0MTD' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.63 Med: 5.62 Max: 12.84
Current: 4.79

During the past 13 years, the highest EV-to-Revenue of Swedish Orphan Biovitrum AB was 12.84. The lowest was 3.63. And the median was 5.62.

LTS:0MTD's EV-to-Revenue is ranked worse than
75.32% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.34 vs LTS:0MTD: 4.79

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-16), Swedish Orphan Biovitrum AB's stock price is kr254.60. Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr67.54. Therefore, Swedish Orphan Biovitrum AB's PS Ratio for today is 3.77.

Swedish Orphan Biovitrum AB EV-to-Revenue Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

4.30

4.14

4.15

3.81

4.99

Swedish Orphan Biovitrum AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																3.81	4.22	4.47	4.52	4.99

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-Revenue falls into.

Swedish Orphan Biovitrum AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Swedish Orphan Biovitrum AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	105975.475	/	22122
	=	4.79

Swedish Orphan Biovitrum AB's current Enterprise Value is kr105,975 Mil.
Swedish Orphan Biovitrum AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr22,122 Mil.

Swedish Orphan Biovitrum AB (LTS:0MTD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Swedish Orphan Biovitrum AB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	254.60	/	67.538
	=	3.77

Swedish Orphan Biovitrum AB's share price for today is kr254.60.
Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr67.54.

Swedish Orphan Biovitrum AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK B6E:Germany B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines